- Home
- Â /Â Seres Therapeutics
Seres Therapeutics
Stock Price
$0.8
2024-10-29
Market Capitalization
$131.2 M
2024-10-29
Revenue
$789 K
FY, 2025
Seres Therapeutics Summary
Company Summary
- Overview
- Seres Therapeutics is a clinical stage biotherapeutic company focused on discovering and developing Ecobioticâ„¢ therapeutic products. Ecobioticâ„¢ is a drugs to treat important diseases by targeting the underlying biology of the human microbiome. Currently, the company spans infectious, metabolic, and inflammatory diseases.
- Type
- Public
- Status
- Active
- Founded
- 2010
- HQ
- Cambridge, MA, US | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
David Arkowitz, Executive Vice President, Chief Financial Officer and Head of Business Development
Thomas J. Desrosier, Executive Vice President, Chief Legal Officer and Secretary
Matthew Henn, Executive Vice President, Chief Scientific Officer
Operating MetricsView all
R&D Expenses (SER-109)
$13.3M
24.2%
Q2, 2022
R&D Expenses (SER-287)
$819K
76.4%
Q2, 2022
Facilities Leased, sq. ft.
83.4K
FY, 2021
LocationsView all
1 location detected
Cambridge, MAÂ HQ
United States
200 Sidney St
Seres Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $358.0K
- Net income (Q1, 2026)
- ($19.9M)
- Cash (Q1, 2026)
- $29.8M
- EBIT (Q1, 2026)
- ($20.9M)
- Enterprise value
- $181.9M